Denali Therapeutics - DNLI Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DNLI shares.
View DNLI analyst ratings or view top-rated stocks.

13 analysts have issued 12 month price objectives for Denali Therapeutics' shares. Their DNLI share price forecasts range from $32.00 to $105.00. On average, they expect the company's share price to reach $54.58 in the next year. This suggests a possible upside of 136.9% from the stock's current price.
View analysts price targets for DNLI or view top-rated stocks among Wall Street analysts.

Denali Therapeutics' stock was trading at $27.81 at the beginning of 2023. Since then, DNLI stock has decreased by 17.2% and is now trading at $23.04.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our DNLI earnings forecast.

Denali Therapeutics Inc. (NASDAQ:DNLI) issued its quarterly earnings data on Monday, February, 27th. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.02. The company earned $10.28 million during the quarter, compared to analyst estimates of $11.29 million. Denali Therapeutics had a negative net margin of 300.55% and a negative trailing twelve-month return on equity of 35.67%. The business's revenue was down 17.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.62) EPS.

ETFs with the largest weight of Denali Therapeutics (NASDAQ:DNLI) stock in their portfolio include Psyk Etf (PSYK), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Biotechnology ETF (IBBQ) and Vanguard Russell 2000 Growth ETF (VTWG).

1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), NVIDIA (NVDA), Invitae (NVTA) and Pretium Resources (PVG).

(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DNLI stock can currently be purchased for approximately $23.04.

Denali Therapeutics (NASDAQ:DNLI) has a market capitalization of $3.15 billion and generates $108.46 million in revenue each year. The company earns $-325,990,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.

The company employs 380 workers across the globe.

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.denalitherapeutics.com. The company can be reached via phone at (615) 866-8548 or via email at hansen@dnli.com.